Abstract
Letters1 June 1997High-Dose Chemotherapy for Breast CancerWilliam J. Gradishar, MD and Martin S. Tallman, MDWilliam J. Gradishar, MDNorthwestern University, Chicago, IL 60611Search for more papers by this author and Martin S. Tallman, MDNorthwestern University, Chicago, IL 60611Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-11-199706010-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the correspondence from Dr. Rushing and de Vries and colleagues. We understand Dr. Rushing's point that some physicians believe that there is adequate evidence from phase II trials to justify the use of a new therapy without confirmation from a phase III randomized trial comparing the current standard therapy to the new treatment. However, we believe it is premature to assume that high-dose chemotherapy is superior to conventional-dose chemotherapy for women with high-risk early-stage breast cancer, despite the encouraging preliminary data cited by Peters and colleagues [1]. Few long-term outcome data (survival) or toxicity data for ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
